Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Targeting increased levels of APP in Down syndrome: Posiphen-mediated reductions in APP and its products reverse endosomal phenotypes in the Ts65Dn mouse model.

Alzheimer's & dementia : the journal of the Alzheimer's Association - 1 Feb 2021

Chen Xu-Qiao, Salehi Ahmad, Pearn Matthew L, Overk Cassia, Nguyen Phuong D, Kleschevnikov Alexander M, Maccecchini Maria, Mobley William C

Abstract excerpt

OBJECTIVE: Recent clinical trials targeting amyloid beta (Aβ) and tau in Alzheimer's disease (AD) have yet to demonstrate efficacy. Reviewing the hypotheses for AD pathogenesis and defining possible links between them may enhance insights into both upstream initiating events and downstream mechanisms, thereby promoting discovery of novel treatments. Evidence that in Down syndrome (DS), a population markedly...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Alzheimer Disease
Share to Amyloid beta-Peptides

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Amyloid beta-Protein Precursor

Share to Cholinesterase Inhibitors

Share to Down Syndrome

Share to Endosomes

Share to Neurons

Share to Phosphorylation

Source

Open in PubMed Open full text

Identifiers

PMID: 32975365
DOI: 10.1002/alz.12185
PMCID: PMC7984396

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Targeting increased levels of APP in Down syndrome: Posiphen-mediated reductions in APP and its products reverse endosomal phenotypes in the Ts65Dn mouse model.PMID 32975365Read ↗

Antisense oligonucleotides directed against App and Rab5 normalized endosomal Rab activity and reversed DS-AD-linked degenerative phenotypes in the Dp16 mouse model of Down syndrome.Semantic proximity Read ↗

Pharmacological approaches to improving cognitive function in Down syndrome: current status and considerationsSemantic proximity Read ↗

Temporal and brain region‐specific elevations of soluble Amyloid‐β40‐42 in the Ts65Dn mouse model of Down syndrome and Alzheimer’s diseaseSemantic proximity Read ↗

From understanding to action: Exploring molecular connections of Down syndrome to Alzheimer's disease for targeted therapeutic approachSemantic proximity Read ↗

Therapeutic potential of APP antisense oligonucleotides for Alzheimer’s disease and down syndrome-related Alzheimer’s diseaseSemantic proximity Read ↗

Amyloid precursor protein dosage normalization rescues neurogenesis and Alzheimer’s Disease phenotypes associated with Down SyndromeSemantic proximity Read ↗

Impact of increased APP gene dose in Down syndrome and the Dp16 mouse modelSemantic proximity Read ↗

Reduced synaptic proteins and SNARE complexes in Down syndrome with Alzheimer's disease and the Dp16 mouse Down syndrome model: Impact of APP gene doseSemantic proximity Read ↗

Alzheimer's disease in Down syndrome: An overlooked population for prevention trialsSemantic proximity Read ↗

Down syndrome and Alzheimer's disease: common molecular traits beyond the amyloid precursor protein.Semantic proximity Read ↗

Rodent Modeling of Alzheimer's Disease in Down Syndrome: In vivo and ex vivo ApproachesSemantic proximity Read ↗

The Impact of APP on Alzheimer-like Pathogenesis and Gene Expression in Down Syndrome iPSC-Derived NeuronsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.